{"id":391450,"date":"2015-02-19T00:00:00","date_gmt":"2015-02-19T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbason0715-biopharma-prostate-cancer-first-line-chemotherapy-naive-metastatic-castrate-resistant-decisionbase-us\/"},"modified":"2026-03-31T09:04:07","modified_gmt":"2026-03-31T09:04:07","slug":"dbason0715-biopharma-prostate-cancer-first-line-chemotherapy-naive-metastatic-castrate-resistant-decisionbase-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbason0715-biopharma-prostate-cancer-first-line-chemotherapy-naive-metastatic-castrate-resistant-decisionbase-us\/","title":{"rendered":"Prostate Cancer (First-Line [Chemotherapy-Naive] Metastatic Castrate-Resistant) | DecisionBase | US | 2015"},"content":{"rendered":"<p><em>What Advantages Do Surveyed Oncologists and Payers Believe Emerging Therapies Must Offer to Gain Traction in This Increasingly Competitive Market?<\/em><\/p>\n<p>In recent years, several new, high-priced therapies have been approved for the first-line (chemotherapy-naive) treatment of metastatic castrate-resistant prostate cancer (mCRPC), making this lucrative market more dynamic and competitive. The launch of these agents has significantly altered the treatment algorithm and improved the outlook for patients; nevertheless, our research indicates that significant clinical and commercial opportunity remains for therapies that can further prolong overall survival (OS). Several therapies are in late-stage development for first-line (chemotherapy-naive) mCRPC, although we do not anticipate that all of them will be approved for this indication.<\/p>\n","protected":false},"template":"","class_list":["post-391450","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-prostate-cancer","biopharma-product-special-topics-other","biopharma-geography-us","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391450","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391450\/revisions"}],"predecessor-version":[{"id":394573,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391450\/revisions\/394573"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391450"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}